Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.

GlobalData has predicted that KarXT will launch in the US next year, and achieve sales of $1.1 billion by 2031 thanks to its safety profile and ability to broadly target symptoms of schizophrenia ...

“KarXT is the first new class of treatment for ... as compared to current antipsychotic medicines, which mostly target dopamine or serotonin receptors. Zai Lab has an exclusive license from ...

The US Food and Drug Administration (FDA) is poised to regulate a "potential first-in-class antipsychotic", known as KarXT, said Medscape. About one in 300 people worldwide are affected by ...

Bristol spent $14 billion earlier this year to acquire Karuna Therapeutics for Cobenfy, the drug formerly called KarXT. Cobenfy gained ... Bristol's Cobenfy both target muscarinic receptors ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for the treatment of schizophrenia in adults.

"In clinical trials, KarXT demonstrated statistically significant reductions of schizophrenia symptoms along with a tolerable safety profile. If approved, KarXT has the potential to redefine the ...